<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="73321"><DrugName>raloxifene hydrochloride (hereditary hemorrhagic telangiectasia), CSIC</DrugName><DrugNamesKey><Name id="42758207">raloxifene</Name><Name id="42758208">raloxifene hydrochloride</Name></DrugNamesKey><DrugSynonyms><Name><Value>raloxifene</Value><Types><Type>INN</Type></Types></Name><Name><Value>raloxifene hydrochloride</Value><Types><Type>USAN</Type></Types></Name><Name><Value>raloxifene hydrochloride (hereditary hemorrhagic telangiectasia), CSIC</Value></Name><Name><Value>84449-90-1</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>82640-04-8</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="21336">Consejo Superior De Investigaciones Cientificas</CompanyOriginator><CompaniesSecondary><Company id="21336">Consejo Superior De Investigaciones Cientificas</Company></CompaniesSecondary><CrossReferences><SourceEntity id="21336" type="Company"><TargetEntity id="5035554804" type="organizationId">Agencia Estatal Consejo Superior de Investigaciones Cientificas</TargetEntity></SourceEntity><SourceEntity id="1879" type="ciIndication"><TargetEntity id="I78.0" type="ICD10"/><TargetEntity id="10019883" type="MEDDRA"/><TargetEntity id="D013683" type="MeSH"/><TargetEntity id="774" type="ORPHANET"/><TargetEntity id="-470984576" type="omicsDisease"/><TargetEntity id="1636" type="siCondition"/></SourceEntity><SourceEntity id="846" type="Action"><TargetEntity id="857" type="Mechanism">Selective Estrogen Receptor Modulators (SERM)</TargetEntity><TargetEntity id="1283" type="Mechanism">Drugs Acting on Estrogen Receptors (ER) </TargetEntity></SourceEntity><SourceEntity id="PTGT-00096" type="ciTarget"><TargetEntity id="1043155650943" type="siTarget">Serine/threonine-protein kinase receptor R3</TargetEntity><TargetEntity id="-1908094858" type="omicsTarget"/></SourceEntity><SourceEntity id="PTGT-00413" type="ciTarget"><TargetEntity id="157908505020223" type="siTarget">Endoglin</TargetEntity><TargetEntity id="953" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="CU">Clinical</PhaseTerminated><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsSecondary><Indication id="1879">Hereditary hemorrhagic telangiectasia</Indication></IndicationsSecondary><ActionsPrimary><Action id="846">Estrogen receptor modulator</Action><Action id="5396">Endoglin stimulator</Action><Action id="8206">Alk-1 protein kinase stimulator</Action></ActionsPrimary><ActionsSecondary><Action id="2667">Antiarteriosclerotic</Action></ActionsSecondary><Technologies><Technology id="603">Systemic formulation unspecified</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2017-05-25T12:24:10.000Z</LastModificationDate><ChangeDateLast>2013-09-25T00:00:00.000Z</ChangeDateLast><AddedDate>2011-09-06T11:38:41.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="21336" linkType="Company"&gt;Consejo Superior De Investigaciones Cientificas&lt;/ulink&gt; (CSIC) was developing a formulation of &lt;ulink linkID="6681" linkType="Drug"&gt;raloxifene hydrochloride&lt;/ulink&gt;, a benzothiophene selective estrogen receptor modulator, which is thought to increase the production of Endoglin and Alk-1 protein kinase, for the potential treatment of hereditary hemorrhagic telangiectasia (HHT). By June 2010, clinical observational studies had been conducted in HHT postmenopausal women [&lt;ulink linkID="1220127" linkType="Reference"&gt;1220127&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In August 2010, the FDA awarded the drug Orphan status [&lt;ulink linkID="1220137" linkType="Reference"&gt;1220137&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2010, the drug received Orphan status from the EMA  [&lt;ulink linkID="1220127" linkType="Reference"&gt;1220127&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="21336">Consejo Superior De Investigaciones Cientificas</Company><Country id="ES">Spain</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1879">Hereditary hemorrhagic telangiectasia</Indication><StatusDate>2013-09-25T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="21336">Consejo Superior De Investigaciones Cientificas</Company><Country id="ES">Spain</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="1879">Hereditary hemorrhagic telangiectasia</Indication><StatusDate>2010-06-22T00:00:00.000Z</StatusDate><Source id="1220127" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="21336">Consejo Superior De Investigaciones Cientificas</OwnerCompany><Country id="US">US</Country><Indication id="1879">Hereditary hemorrhagic telangiectasia</Indication><AwardedIndication>Treatment of hereditary hemorrhagic telangiectasia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2010-08-20T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="21336">Consejo Superior De Investigaciones Cientificas</OwnerCompany><Country id="EU">EU</Country><Indication id="1879">Hereditary hemorrhagic telangiectasia</Indication><AwardedIndication>Treatment of hereditary haemorrhagic telangiectasia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2010-06-10T00:00:00.000Z</MileStoneDate><Source id="1220127" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="21336">Consejo Superior De Investigaciones Cientificas</OwnerCompany><Country id="EU">EU</Country><Indication id="1879">Hereditary hemorrhagic telangiectasia</Indication><AwardedIndication>Treatment of hereditary haemorrhagic telangiectasia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2010-02-03T00:00:00.000Z</MileStoneDate></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00096"><Name>Alk-1 protein kinase</Name><SwissprotNumbers><Swissprot>P37023</Swissprot><Swissprot>P80203</Swissprot><Swissprot>Q61288</Swissprot></SwissprotNumbers></Target><Target id="PTGT-00413"><Name>Endoglin</Name><SwissprotNumbers><Swissprot>P17813</Swissprot><Swissprot>P37176</Swissprot><Swissprot>Q63961</Swissprot></SwissprotNumbers></Target><Target id="PTGT-00692"><Name>Estrogen receptor</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>c1cc(ccc1c2c(c3ccc(cc3s2)O)C(=O)c4ccc(cc4)OCCN5CCCCC5)O</Smiles><Smiles>c1cc(ccc1c2c(c3ccc(cc3s2)O)C(=O)c4ccc(cc4)OCCN5CCCCC5)O.Cl</Smiles></StructureSmiles><hasSWOTs>N</hasSWOTs></drugRecordOutput>